X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Torrent Pharma with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs ACTAVIS (US) - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 TORRENT PHARMA   ACTAVIS
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
ACTAVIS
Dec-14
TORRENT PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,55019,647-   
Low Rs1,14411,984-   
Sales per share (Unadj.) Rs354.73,537.9-  
Earnings per share (Unadj.) Rs40.1-441.5-  
Cash flow per share (Unadj.) Rs64.2324.6-  
Dividends per share (Unadj.) Rs14.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs273.17,673.6-  
Shares outstanding (eoy) m169.22265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.84.5 84.9%   
Avg P/E ratio x33.6-35.8 -93.8%  
P/CF ratio (eoy) x21.048.7 43.0%  
Price / Book Value ratio x4.92.1 239.2%  
Dividend payout %34.90-   
Avg Mkt Cap Rs m227,8974,205,366 5.4%   
No. of employees `00014.721.6 68.1%   
Total wages/salary Rs m11,3530-   
Avg. sales/employee Rs Th4,083.043,552.1 9.4%   
Avg. wages/employee Rs Th772.30-   
Avg. net profit/employee Rs Th461.3-5,434.8 -8.5%   
INCOME DATA
Net Sales Rs m60,021940,725 6.4%  
Other income Rs m2,988-2,348 -127.3%   
Total revenues Rs m63,009938,377 6.7%   
Gross profit Rs m13,493120,850 11.2%  
Depreciation Rs m4,086203,701 2.0%   
Interest Rs m3,08529,672 10.4%   
Profit before tax Rs m9,310-114,872 -8.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-8,426 0.0%   
Tax Rs m2,529-5,906 -42.8%   
Profit after tax Rs m6,781-117,393 -5.8%  
Gross profit margin %22.512.8 175.0%  
Effective tax rate %27.25.1 528.3%   
Net profit margin %11.3-12.5 -90.5%  
BALANCE SHEET DATA
Current assets Rs m52,623495,642 10.6%   
Current liabilities Rs m52,022361,468 14.4%   
Net working cap to sales %1.014.3 7.0%  
Current ratio x1.01.4 73.8%  
Inventory Days Days12058 206.1%  
Debtors Days Days7666 115.0%  
Net fixed assets Rs m85,016114,872 74.0%   
Share capital Rs m8460-   
"Free" reserves Rs m45,3760-   
Net worth Rs m46,2222,040,399 2.3%   
Long term debt Rs m41,1151,069,209 3.8%   
Total assets Rs m142,4323,739,379 3.8%  
Interest coverage x4.0-2.9 -139.9%   
Debt to equity ratio x0.90.5 169.7%  
Sales to assets ratio x0.40.3 167.5%   
Return on assets %6.9-2.3 -295.3%  
Return on equity %14.7-5.8 -255.0%  
Return on capital %14.2-3.0 -471.4%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m10,9800-   
CASH FLOW
From Operations Rs m8,942161,541 5.5%  
From Investments Rs m-47,070-386,791 12.2%  
From Financial Activity Rs m34,174217,320 15.7%  
Net Cashflow Rs m-3,655-7,929 46.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 72.02 Rs / USD

Compare TORRENT PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare TORRENT PHARMA With: PFIZER  JUBILANT LIFE SCIENCES  MERCK LTD  NATCO PHARMA  STERLING BIOTECH  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views On News

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

Are Foreign Investors Heading Back to the Indian Stock Markets?(Chart Of The Day)

Dec 3, 2018

After months of heavy FII selling, November witnessed a return on foreign money into Indian equities...

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Dec 14, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - DISHMAN PHARMA COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS